Hillinger Sven, Weder Walter
Front Radiat Ther Oncol. 2010;42:115-121. doi: 10.1159/000262466. Epub 2009 Nov 24.
Stage III includes a large variety of clinical situations from chest wall invasion together with intralobar lymph node metastasis to any size of a lung cancer in combination with mediastinal lymph node involvement (N2/N3). Furthermore, the prognosis of patients with lymph node metastasis depends largely on the extent of the disease, which may range from micro-metastasis occasionally found during surgery to bulky and/or multilevel involvement of the mediastinum or extracapsular infiltration. Not surprising the optimal treatment including the role of surgery for stage IIIA (N2) and stage IIIB (T4/N3) non-small cell lung cancer is discussed controversially. Adequate analysis of the clinical stage is key to select the best treatment. In general, patients benefit from surgery, when a radical resection can be achieved with a low morbidity and mortality. A multidisciplinary approach is indicated in most patients, which present with stage III disease at diagnosis. Preferentially patients should be treated in study protocols whenever they are available. Radical surgery including chest wall resection may result in a 5-year survival rate of up to 50% in T3N1 disease. Adjuvant chemotherapy is recommended and radiotherapy is reserved for cases with unclear resection margins. Clinical trials of preoperatively proven N2 patients could show a better outcome when downstaging is achieved after neoadjuvant chemo- or chemoradiotherapy prior to surgery. Patients who may need a pneumonectomy should be selected with caution since some centers experience a high perioperative mortality rate. If unforeseen N2 disease is found during surgery, an adjuvant therapy is recommended. Patients with T4 tumors (infiltration of great vessels, trachea, esophagus, vertebral bodies, etc.) show an increasing 5-year survival from 15 to 35% after radical resection with acceptable perioperative mortality if treated in experienced centers. In stage III non-small cell lung cancer, surgery should be performed within a multimodality approach. Surgery should be recommended when resection is radical including systematic lymph node dissection and mortality and morbidity are low.
III期包括多种临床情况,从伴有叶内淋巴结转移的胸壁侵犯到任何大小的肺癌合并纵隔淋巴结受累(N2/N3)。此外,有淋巴结转移的患者的预后在很大程度上取决于疾病的范围,其范围可能从手术中偶尔发现的微转移到纵隔的大块和/或多水平受累或包膜外浸润。毫不奇怪,关于包括手术在IIIA期(N2)和IIIB期(T4/N3)非小细胞肺癌中的作用在内的最佳治疗方法存在争议。对临床分期进行充分分析是选择最佳治疗方法的关键。一般来说,当能够以低发病率和死亡率实现根治性切除时,患者可从手术中获益。大多数诊断为III期疾病的患者都需要采用多学科方法。只要有研究方案,应优先让患者参加。包括胸壁切除的根治性手术在T3N1疾病中可能导致高达50%的5年生存率。建议进行辅助化疗,放疗则保留用于切缘不清楚的病例。术前证实为N2的患者在手术前经过新辅助化疗或放化疗实现降期后,临床试验可能显示出更好的结果。可能需要进行肺切除术的患者应谨慎选择,因为一些中心的围手术期死亡率较高。如果在手术中发现意外的N2疾病,建议进行辅助治疗。T4肿瘤(侵犯大血管、气管、食管、椎体等)的患者在经验丰富的中心接受根治性切除后,5年生存率从15%提高到35%,围手术期死亡率可接受。在III期非小细胞肺癌中,手术应在多模式治疗方法中进行。当切除是根治性的,包括系统性淋巴结清扫,且死亡率和发病率较低时,应建议进行手术。